Pixyl Medical

La Tronche, France (Grenoble region)  All France companies → Founded 2015
Imaging AI Specialist Specialty-Focused AI
Acquired (by Gleamer on March 12, 2025) — $3.19M - $4.18M

About Pixyl Medical

Pixyl Medical is a French medtech company that develops AI-powered software solutions for neuroimaging analysis, aiming to improve patient care by providing advanced tools to radiologists and clinicians. Their flagship product, Pixyl.Neuro, leverages deep learning and generative AI to automatically analyze brain MRI images. This technology is designed to rapidly detect anomalies and changes associated with neuroinflammatory and neurodegenerative disorders, such as multiple sclerosis (MS), dementia, stroke, and traumatic brain injury.

For physicians, Pixyl.Neuro offers several key benefits. It automates time-consuming tasks like lesion counting and comparison with prior exams, reducing variability in measurements and standardizing patient monitoring. The software provides quantitative reports on lesion volume, brain atrophy, and white matter hyperintensities, along with annotated MRI images, all within minutes. This clinically relevant information assists in early diagnosis, objective monitoring, and tailoring treatment plans for patients. Pixyl.Neuro has received CE-mark class IIa certification in the European Union and FDA 510(k) clearance in the US, ensuring its quality and regulatory compliance.

Focus Areas

neuroimaging artificial intelligence multiple sclerosis dementia stroke traumatic brain injury neurodegenerative diseases neuroinflammatory disorders

Business Intelligence

Key InvestorsElaia, Holnest, Bpifrance, Credit Agricole, IT-Translation, Davycrest Nominees, NETVA, Club Holnest, Crédit Agricole Alpes Développement
PartnershipsBrainomix, Incepto, Siemens, GE HealthCare, UC Davis
AcquisitionsAcquired by Gleamer (March 2025)
TechnologyAI-powered, deep learning, generative AI, cloud-native (SaaS)
FDA Clearances1 cleared products (estimated)

What Physicians Need to Know

Neuroimaging AI Specialization
Pixyl Medical specializes in advanced AI for analyzing brain MRI images to detect anomalies and changes related to neuroinflammatory and neurodegenerative disorders, including Multiple Sclerosis, dementia, stroke, and traumatic brain injury.
Rapid Analysis
Their proprietary AI algorithms and fast computing infrastructure enable brain MRI analysis to be completed in less than five minutes, even with minimal MRI protocols.
Regulatory Clearances
Pixyl.Neuro has received FDA 510(k) clearance (Class II) in the United States and is certified as a CE-marked Class IIa medical device under European Medical Device Regulations (MDR), ensuring high quality and safety.
Disease Monitoring & Prediction
The software supports rapid detection, early diagnosis, and objective monitoring of neurological disorders. It can quantify brain region volumes, identify abnormal atrophy, and has shown the ability to predict disability progression in Multiple Sclerosis patients.
Workflow Integration
Pixyl's solutions are designed to integrate seamlessly into existing radiology workflows, providing clinically actionable information and automating time-consuming tasks like lesion counting and comparison with prior exams.
Physician Tip

For physicians, Pixyl Medical's AI-powered neuroimaging offers significant advantages. The rapid analysis (under 5 minutes) of brain MRI images allows for quicker diagnostic support and monitoring of neuroinflammatory and neurodegenerative disorders like MS and Alzheimer's. The quantitative data on lesion volume, brain atrophy, and longitudinal analysis helps in objective disease monitoring and can aid in differential diagnoses. This is particularly crucial with the advent of disease-modifying treatments, as it helps highlight disease activity and monitor evolution. The seamless integration into existing radiology workflows and the automation of tasks can reduce variability in measurements and free up radiologists' time for more complex cases, ultimately reinforcing radiology workflows and improving patient care.

Pixyl's solutions are designed for seamless integration into the radiology workflow. They have established partnerships for distribution and marketing with companies like Siemens, GE Healthcare, and Incepto. Pixyl.Neuro is available directly from Pixyl and through select distributors.

Products by Pixyl Medical

No products listed for this company yet. Know of one? Suggest it →

Reviews & Opinions

No web reviews on file yet for Pixyl Medical. Check back later for aggregated opinions from across the web.

Videos

News, demos, and interviews about Pixyl Medical.

Loading videos...

Videos load interactively. If none appear, search YouTube for Pixyl Medical →

View all on YouTube

Press & Coverage

NeurologyLive
FDA Clears AI-Powered Brain MRI Software Pixyl.Neuro - NeurologyLive
Pixyl announced that the FDA has granted 510(k) clearance to Pixyl.Neuro, an AI-powered medical technology designed to detect anomalies and changes in brain MR images for neuroinflammatory and neurodegenerative disorders. The software has also received CE-mark class IIa certification in the European Union and is used in over 12 countries.
2023-11
Pixyl Medical (Press Release)
Pixyl receives FDA clearance for AI-powered brain MRI software Pixyl.Neuro
Pixyl announced FDA 510(k) clearance for Pixyl.Neurou2122, their next-generation AI software for brain MRI analysis, which has shown enhanced detection rates up to 28%. The software aims to support rapid detection, early diagnosis, and objective monitoring of neurological disorders, leveraging generative AI technology.
2023-11
Radiology Business
FDA clears AI-powered brain MRI software from French firm Pixyl - Radiology Business
The U.S. Food and Drug Administration has cleared Pixyl.Neuro, an AI-powered software for analyzing brain MRIs to aid in diagnosing and monitoring neurological disorders. The Grenoble, France-based firm states its goal is to improve detection rates while reducing radiologists' read times.
2023-11
Diagnostic Imaging
Emerging AI Software for Brain MRI Gets FDA Nod | Diagnostic Imaging
The FDA has granted 510(k) clearance for Pixyl.Neurou2122, an AI-powered software that may enhance MRI detection and follow-up of patients with neurological disorders like Alzheimer's disease and multiple sclerosis. The software reportedly provides automated brain MRI analysis in under five minutes.
2023-11
PMCF
How Artificial Intelligence is Rewriting the Playbook for Healthcare M&A
France-based Gleamer, a leader in AI medical imaging, expanded its capabilities by acquiring Pixyl Medical (neurological MRI) and Caerus Medical (lumbar MRI) in March 2025, enhancing its AI-driven diagnostic tools across various imaging modalities.
2025-06
openPR.com
Artificial Intelligence in Healthcare Market 2025 | Growth,
Gleamer's portfolio expansions through acquiring Pixyl Medical and Caerus Medical enhance its AI diagnostic capabilities across various imaging modalities, including neuro and lumbar MRI.
2025-08
openPR.com
AI-Powered Imaging Diagnostics Market to Reach USD 9.73 Billion - openPR.com
In March 2025, Gleamer acquired Pixyl Medical and Caerus Medical, expanding into multiple MRI AI applications, illustrating consolidation within imaging AI capabilities.
2026-02
PubMed
Resting-State Functional Connectivity Profile of Insular Subregions - PubMed
This peer-reviewed article, co-authored by researchers from Pixyl Medical, investigates the resting-state functional connectivity profiles of insular subregions using fMRI techniques and a large cohort of healthy participants. The study aims to provide a more detailed pattern of connectivity for comparison between patients.
2024-07

Frequently Asked Questions

Pixyl Medical offers Pixyl.Neuro, an AI-powered software for brain MRI analysis that supports the diagnosis and monitoring of neuroinflammatory and neurodegenerative disorders. Specifically, Pixyl.Neuro.MS is designed for Multiple Sclerosis, providing quantitative reports on lesion location, volume, and evolution. Pixyl.Neuro.BV focuses on volumetric analyses for neurodegenerative pathologies, quantifying brain region volumes and identifying atrophy, which can be relevant for conditions like dementia and traumatic brain injury. While Pixyl.Neuro is geared to detect anomalies and changes in brain MR images for neuroinflammatory and neurodegenerative disorders, its application to acute stroke is not explicitly detailed as a primary product focus, though general neurological disorders are mentioned.
Pixyl Medical's Pixyl.Neuro software has received FDA 510(k) clearance in the United States and is certified as a CE-marked class IIa medical device under the new Medical Device Regulations in the European Union. This demonstrates their adherence to high-quality medical device development and AI guidelines.
The provided information does not detail the specific pricing structure or typical costs for Pixyl Medical's solutions. However, it is noted that their solutions are available directly from Pixyl and from select distributors. For specific pricing inquiries, direct contact with Pixyl Medical or their distributors would be necessary.
While the specifics of training are not detailed, Pixyl Medical emphasizes integrating AI support directly into existing infrastructure and regular clinical workflows. They also state that in case of connection problems, users should contact Pixyl customer support. This suggests direct support is available for technical issues.
Yes, Pixyl Medical has established partnerships. They have a distribution partnership with Brainomix, an AI-powered medtech solutions company, to distribute Pixyl's Neuro.MS solution in specific European markets. Pixyl also collaborates with research institutions like Inria and the Grenoble Institute of Neuroscience (GIN) for ongoing research and development. Additionally, they are a partner in the PRIMUS (Projection In Multiple Sclerosis) research project.
Pixyl Medical, founded in 2015, is an award-winning French medtech company specializing in AI-powered MRI solutions. Their Pixyl.Neuro software has been used in over 12 countries across Europe, North America, and Africa, with a four-fold increase in usage since December 2022. They have also secured significant funding rounds, indicating investor confidence. They were acquired by Gleamer.

Related Companies

CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]

Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]

OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]

Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]

MedTalk AI is an Australian-based healthcare AI company focused on streamlining clinical documentation for physicians and other healthcare professionals. The company’s flagship product is an ambient AI medical scribe that listens to real clinical conversations and converts them into structured, accurate notes in real-time. This technology aims to free clinicians from the burden of manual […]

allergoSMART is a healthcare AI company that offers the world’s first AI-based complete solution for personalized mite allergen avoidance. The company’s system, allergoSMART, provides a unique AI digital solution for individuals with dust mite allergies, combining targeted prevention and treatment through comprehensive home environment optimization. [3] It integrates symptom tracking, telemedicine, and air purification into […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.